332
Pathway
Gefitinib Action Pathway
Gefitinib is an anti-EGFR drug used in the treatment of some cancers. EGFR is linked multiple signalling pathways involved in tumour growth and angiogenesis such as the Ras/Raf pathway and the PI3K/Akt pathways. These pathways ultimately lead to the activation of transcription factors such as Jun, Fos, and Myc, as well as cyclin D1, which stimulates cell growth and mitosis. Uncontrolled cell growth and mitosis leads to cancer. Gefitinib acts as an anticancer drug by binding to the intracellular tyrosine kinase domain of the EGFR and blocking its activity. This in turn inhibits downstream signalling and prevents tumour growth.
Drug Action
PW000252
Top
PathwayVisualizationContext268
1000
1000
#000099
PathwayVisualization172
332
Gefitinib Pathway
Gefitinib is an anti-EGFR drug used in the treatment of some cancers. EGFR is linked multiple signalling pathways involved in tumour growth and angiogenesis such as the Ras/Raf pathway and the PI3K/Akt pathways. These pathways ultimately lead to the activation of transcription factors such as Jun, Fos, and Myc, as well as cyclin D1, which stimulates cell growth and mitosis. Uncontrolled cell growth and mitosis leads to cancer. Gefitinib acts as an anticancer drug by binding to the intracellular tyrosine kinase domain of the EGFR and blocking its activity. This in turn inhibits downstream signalling and prevents tumour growth.
Drug
1
584
Gefitinib Inhibition of Epidermal growth factor receptor
InhibitorySubPathway
978
8849
Compound
2
979
822
ProteinComplex
14
1527
20127143
Gazdar AF: Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 2010 Mar;29(1):37-48. doi: 10.1007/s10555-010-9201-z.
332
Pathway
1528
20130423
Lurje G, Lenz HJ: EGFR signaling and drug discovery. Oncology. 2009;77(6):400-10. doi: 10.1159/000279388. Epub 2010 Feb 2.
332
Pathway
1
Cell
CL:0000000
1
Homo sapiens
9606
Eukaryote
Human
1
Cytosol
GO:0005829
11
Extracellular Space
GO:0005615
10
Cell Membrane
GO:0005886
36
Membrane
GO:0016020
2
1
1
1
PW_BS000002
15
11
1
PW_BS000015
14
10
1
PW_BS000014
228
36
1
PW_BS000024
308
10
1
1
PW_BS000024
8849
Gefitinib
HMDB0014462
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. [Wikipedia]
184475-35-2
123631
49668
110217
DB00317
COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
C22H24ClFN4O3
InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
XGALLCVXEZPNRQ-UHFFFAOYSA-N
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
446.902
446.152096566
-4.22
1
gefitinib
0
0
4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline;Iressa;N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine;Zd 1839
PW_C008849
Gefitin
3497
2
3504
15
1351
Epidermal growth factor receptor
P00533
Isoform 2 may act as an antagonist of EGF action
HMDBP01456
EGFR
7p12
AY588246
1
2.7.10.1
3399
2
3407
14
11650
228
80850
308
822
Epidermal growth factor receptor
1
PW_P000822
946
1351
2
170
PW_T000170
199
8849
1
Compound
15
2
Right
6992
8849
2
158
false
220
540
10
regular
300
280
7005
8849
15
158
false
220
60
10
regular
300
280
7006
8849
2
158
true
255
40
10
regular
300
280
3058
1351
14
80
false
715
610
8
subunit
regular
200
130
2675
822
172
14
3047
3058
10605
M520 680 C553 680 714 681 755 680
148
false
18
false
true
M 700.329739888295 339.2403672165248 L 709 327 L 717.670260111705 314.7596327834752
10606
M11 12 C34 28 74 55 98 72
5
true
18
10633
M370 540 C369 493 370 373 370 340
83
false
18
true
M 362.22536847725314 527.1720966371931 L 370 540 L 377.22197442810915 526.8530199148345
false
10634
M255 90 C225 90 151 33 175 50
83
true
18
264
170
172
585
7005
10633
Left
586
7006
10634
Right
660
584
172
14
true
955
335
16
regular
627
6992
10605
Left
357
2675
10606
Right
499
M115 530 C115 480 165 430 215 430 C373 430 580 430 738 430 C788 430 838 480 838 530 C838 621 838 739 838 830 C838 880 788 930 738 930 C580 930 373 930 215 930 C165 930 115 880 115 830 C115 739 115 621 115 530
1
true
6
723.0
500.0